Neuren Pharmaceuticals Ltd at Jefferies Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us today at the day two of Jefferies Healthcare Conference. My name is Dave Stantan, I'm part of the Australian healthcare research team. Delighted to have Jon Pilcher here with us today, CEO of Neuren, to talk all things Neuren. And we've got a presentation, and hopefully open it up for questions at the end. If you've gotten a question, just -- there'll be a microphone coming around.
So Jon, thank you very much and over to you.
Thanks a lot, David. Good afternoon, everyone. Really appreciate you coming to listen. As always, just to remind you, there's some forward-looking statements in the slides and what I say, that is subject to risks, it leads to different outcomes.
So delighted to be here from Australia. So Neuren's listed on the Australian Stock Exchange. Headquartered in Australia, but most of our development work has been done in the US, always been very US focused. Market cap is about AUD1.7 billion, which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
